Related Experiment Video
Updated: Jul 15, 2025

Purification of a High Molecular Mass Protein in Streptococcus mutans
Published on: September 14, 2019
WITHDRAWN: Streptococcus mutans inhibits the growth of Enterococcus via the non-ribosomal cyclic peptide mutanobactin
Abstract:
This manuscript has been withdrawn due to concerns about missing raw data. This work should not be cited as reference for the project. If you have any questions, please contact the corresponding author.
Insights
Streptococcus mutans produces mutanobactin, a cyclic lipopeptide, inhibiting Enterococcus faecalis growth and biofilm formation. E. faecalis resistance involves gelatinase, highlighting mutanobactin's anti-biofilm potential in polymicrobial communities.
Area of Science:
- Microbiology
- Molecular Biology
- Biochemistry
Background:
- Enterococcus faecalis is an opportunistic pathogen causing nosocomial infections, complicated by antibiotic resistance.
- E. faecalis is linked to oral diseases and endodontic treatment failures, necessitating understanding its interactions within microbial communities.
- The interactions between E. faecalis and oral streptococci, crucial for microbiome establishment, are not well understood.
Purpose of the Study:
- To elucidate the mechanism by which Streptococcus mutans inhibits the growth of Enterococcus faecalis.
- To characterize the antimicrobial compound mutanobactin and its production system.
- To investigate the resistance mechanisms of E. faecalis against mutanobactin.
Main Methods:
- Identification and characterization of mutanobactin, a cyclic lipopeptide produced by S. mutans.
- Analysis of the polyketide synthase-nonribosomal peptide synthetase hybrid system (mub locus) responsible for mutanobactin production.
- Assessment of mutanobactin's activity against planktonic and biofilm growth of E. faecalis and other Gram-positive pathogens.
- Investigation of the role of E. faecalis virulence factor gelatinase in mutanobactin resistance.
Main Results:
- Streptococcus mutans produces mutanobactin, a cyclic lipopeptide that inhibits planktonic and biofilm growth of E. faecalis and other Gram-positive pathogens like Staphylococcus aureus.
- Mutanobactin damages the cell envelope of E. faecalis, similar to lipopeptide antibiotics such as daptomycin.
- Enterococcus faecalis resistance to mutanobactin is mediated by the secreted metalloprotease gelatinase.
Conclusions:
- Mutanobactin exhibits significant anti-biofilm potential, making it a promising natural product for therapeutic applications.
- This study provides insights into the complex interactions within polymicrobial communities, particularly between E. faecalis and oral streptococci.
- Understanding E. faecalis dynamics and resistance mechanisms in polymicrobial settings is crucial for managing infections and treatment failures.
Related Concept Videos
Development of Antibiotic Resistance
Antimicrobial Proteins
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...
Gene Regulation in Microbial Communities: Quorum Sensing
Biological Methods for Microbial Control
Defense Against Bacterial Pathogens
Phagocytes
Phagocytes are the frontline soldiers of the immune system. They include neutrophils and macrophages. Neutrophils are the most abundant type of white blood cell and are quickly mobilized to the site of infection. Macrophages are larger cells that patrol...
Combined Effects of Drugs: Synergism
Such synergistic combinations...

